{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:23:34Z","timestamp":1790097814580,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.eururo.2009.04.020","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T04:27:39Z","timestamp":1240374459000},"page":"891-896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory Idiopathic Detrusor Overactivity Incontinence: Patient-Reported Outcome at 4 Weeks"],"prefix":"10.1016","volume":"57","author":[{"given":"Shahid","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalesh","family":"Panicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Roosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohier","family":"Elneil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prokar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare J.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2009.04.020_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2009.04.020_bib2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.04.020_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib4","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1464-410x.2004.04806.x","article-title":"The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK","volume":"93","author":"Turner","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.04.020_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","article-title":"The current and future burden and cost of overactive bladder in five European countries","volume":"50","author":"Reeves","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib6","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1742-1241.2006.01057.x","article-title":"Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care","volume":"60","author":"Odeyemi","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2009.04.020_bib7","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","article-title":"A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.eururo.2009.04.020_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","article-title":"Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report","volume":"55","author":"Apostolidis","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2006.05.044","article-title":"Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures","volume":"68","author":"Abrams","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.04.020_bib10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.ajog.2004.11.052","article-title":"Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study","volume":"192","author":"Werner","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.eururo.2009.04.020_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/nau.10066","article-title":"Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies","volume":"21","author":"Schafer","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2009.04.020_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1464-410X.2003.04312.x","article-title":"A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity","volume":"92","author":"Harper","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.04.020_bib13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","article-title":"A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin","volume":"174","author":"Popat","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/nau.1930140206","article-title":"Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group","volume":"14","author":"Uebersax","year":"1995","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2009.04.020_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","article-title":"Botulinum toxin A (Botox\u00ae) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review","volume":"53","author":"Karsenty","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eururo.2005.12.012","article-title":"Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes","volume":"49","author":"Kalsi","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib17","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","article-title":"Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics","volume":"176","author":"Schmid","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.eururo.2007.12.029","article-title":"Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity","volume":"54","author":"Kalsi","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","article-title":"A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder","volume":"54","author":"Novara","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.urology.2006.02.046","article-title":"Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit","volume":"68","author":"Marschall-Kehrel","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.04.020_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0090-4295(03)00144-4","article-title":"Discrepancy in patient and physician perception of patient\u2019s quality of life related to urinary symptoms","volume":"62","author":"Rodriguez","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.04.020_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.04.020_bib25","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1097\/01.ju.0000143889.00681.3f","article-title":"The effect of botulinum-A toxin on patients with severe urge urinary incontinence","volume":"172","author":"Flynn","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.04.020_bib26","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1464-410X.2007.07186.x","article-title":"Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity","volume":"100","author":"Jeffery","year":"2007","journal-title":"BJU Int"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809004096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809004096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:02:24Z","timestamp":1759582944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283809004096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0302283809004096"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2009.04.020","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory Idiopathic Detrusor Overactivity Incontinence: Patient-Reported Outcome at 4 Weeks","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2009.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}